公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | Ramalingam S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. | Journal of Thoracic Oncology | 66 | 57 | |
2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam S.S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A. | Journal of Clinical Oncology | 405 | 346 | |
2019 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report | Chih-Hsin CHIH-HSIN YANG ; Shepherd F.A; Kim D.-W; Lee G.-W; Lee J.S; Chang G.-C; Lee S.S; Wei Y.-F; Lee Y.G; Laus G; Collins B; Pisetzky F; Horn L. | Journal of Thoracic Oncology | 148 | 126 | |
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2018 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer | Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG ; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. | Journal of Clinical Oncology | 245 | 211 | |
2018 | Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer | Wu Y.-L; CHIH-HSIN YANG ; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. | Journal of Clinical Oncology | 240 | 183 | |
2016 | Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer | Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG ; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. | Journal of Clinical Oncology | 163 | 142 | |
2020 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer | Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG ; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. | Lung Cancer | 23 | 10 | |
2017 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer | CHIH-HSIN YANG ; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T. | Journal of Thoracic Oncology | 78 | 56 | |
2016 | Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity | Ballard P; Yates J.W.T; Yang Z; Kim D.-W; CHIH-HSIN YANG ; Cantarini M; Pickup K; Jordan A; Hickey M; Grist M; Box M; Johnström P; Varnäs K; Malmquist J; Thress K.S; Jänne P.A; Cross D. | Clinical Cancer Research | 550 | 490 | |
2017 | Scientific Advances in Thoracic Oncology 2016 | Soo R.A; Stone E.C.A; Cummings K.M; Jett J.R; Field J.K; Groen H.J.M; Mulshine J.L; Yatabe Y; Bubendorf L; Dacic S; Rami-Porta R; Detterbeck F.C; Lim E; Asamura H; Donington J; Wakelee H.A; Wu Y.-L; Higgins K; Senan S; Solomon B; Kim D.-W; Johnson M; CHIH-HSIN YANG ; Sequist L.V; Shaw A.T; Ahn M.-J; Costa D.B; Patel J.D; Horn L; Gettinger S; Peters S; Wynes M.W; Faivre-Finn C; Rudin C.M; Tsao A; Baas P; Kelly R.J; Leighl N.B; Scagliotti G.V; Gandara D.R; Hirsch F.R; Spigel D.R. | Journal of Thoracic Oncology | 42 | 31 | |
2019 | Time to response in patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) receiving alectinib in the phase ii NP28673 and NP28761 studies | Gadgeel S; Shaw A.T; Barlesi F; Crino L; CHIH-HSIN YANG ; Dingemans A.-M; Kim D.-W; Marinis F; Schulz M; Liu S; Gupta R; Smoljanovic V; Ou S.-H.I. | Lung Cancer: Targets and Therapy | 3 | 1 |